Together, these data provide insight into the regulation of the OX40 co-stimulatory receptor by TCR/gc cytokine signaling and suggest that combined anti-OX40/gc cytokine-directed therapy can provide a novel strategy to boost tumor immunotherapy and revive the function of tumor-reactive CD8 T cells for the treatment of patients with cancer. The gene discussed is CD8A; the disease is neoplasm.